The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance - PubMed (original) (raw)

The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance

E Rockenstein et al. J Neural Transm (Vienna). 2003 Nov.

Abstract

Cerebrolysin is a peptide mixture with neurotrophic effects that might have the ability of both reducing amyloid burden and improving synaptic plasticity in Alzheimer's disease (AD). In order to determine if Cerebrolysin is capable of ameliorating the neurodegenerative and behavioral alterations associated with amyloid beta (A beta) production; transgenic (tg) mice expressing mutant human amyloid precursor protein (APP) under the Thy1 promoter were treated with Cerebrolysin or saline alone starting at 3 or 6 months of age for a total of three months. Animals were then tested behaviorally (at 6 and 9 months of age respectively) in the water maze and then analyzed neuropathologically for amyloid burden, synaptic density, astrogliosis and apoptosis. Performance analysis in the water maze showed that in the younger tg mice cohort, Cerebrolysin treatment significantly ameliorated the performance deficits. In the older cohort, there was a trend toward improved performance in the learning curve. Neuropathological examination showed that in both age/treatment groups, Cerebrolysin promoted synaptic regeneration, and reduced the proportion of neurons displaying DNA fragmentation by the (TdT)-mediated dUTP-biotin nick-end labeling (TUNEL) method. Moreover, Cerebrolysin treatment reduced A beta burden by 43% in the young group and by 27% in the older group. Taken together, these results suggest that Cerebrolysin treatment might have beneficial effects in patients with cognitive impairment by reducing A beta accumulation and promoting the preservation of synaptic terminals.

PubMed Disclaimer

Cited by

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.
Rockenstein E, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E. Rockenstein E, et al. BMC Neurosci. 2015 Nov 26;16:85. doi: 10.1186/s12868-015-0218-7. BMC Neurosci. 2015. PMID: 26611895 Free PMC article.
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice.
Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Jolivalt CG, et al. Exp Neurol. 2010 Jun;223(2):422-31. doi: 10.1016/j.expneurol.2009.11.005. Epub 2009 Nov 18. Exp Neurol. 2010. PMID: 19931251 Free PMC article.
Therapeutic Strategies Aimed at Improving Neuroplasticity in Alzheimer Disease.
Colavitta MF, Barrantes FJ. Colavitta MF, et al. Pharmaceutics. 2023 Jul 31;15(8):2052. doi: 10.3390/pharmaceutics15082052. Pharmaceutics. 2023. PMID: 37631266 Free PMC article. Review.
Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.
Rockenstein E, Ubhi K, Pham E, Michael S, Doppler E, Novak P, Inglis C, Mante M, Adame A, Alvarez XA, Moessler H, Masliah E. Rockenstein E, et al. J Neurosci Res. 2011 Nov;89(11):1812-21. doi: 10.1002/jnr.22712. Epub 2011 Jul 25. J Neurosci Res. 2011. PMID: 21793038 Free PMC article.
Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke.
Chang WH, Park CH, Kim DY, Shin YI, Ko MH, Lee A, Jang SY, Kim YH. Chang WH, et al. BMC Neurol. 2016 Mar 2;16:31. doi: 10.1186/s12883-016-0553-z. BMC Neurol. 2016. PMID: 26934986 Free PMC article. Clinical Trial.

The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance - PubMed (original) (raw)